Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALDX Stock Forecast 2026-2027
$4.24
Current Price
$255.09M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ALDX Price Targets
+206.6%
To High Target of $13.00
+124.1%
To Median Target of $9.50
+65.1%
To Low Target of $7.00
ALDX Price Momentum
+1.4%
1 Week Change
+6.3%
1 Month Change
-15.7%
1 Year Change
-18.1%
Year-to-Date Change
-41.1%
From 52W High of $7.20
+271.9%
From 52W Low of $1.14
📊 TOP ANALYST CALLS
Did ALDX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aldeyra is one of their latest high-conviction picks.
Latest ALDX Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, ALDX has a bullish consensus with a median price target of $9.50 (ranging from $7.00 to $13.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $4.24, the median forecast implies a 124.1% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALDX Analyst Ratings
5
Buy
0
Hold
0
Sell
ALDX Price Target Range
Low
$7.00
Average
$9.50
High
$13.00
Current: $4.24
Latest ALDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 10, 2025 | BTIG | Thomas Shrader | Buy | Reiterates | $9.00 |
| May 19, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $10.00 |
| Apr 7, 2025 | BTIG | Thomas Shrader | Buy | Maintains | $9.00 |
| Apr 4, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $10.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $10.00 |
| Aug 9, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $10.00 |
| Aug 2, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $10.00 |
| May 6, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $10.00 |
| May 6, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $10.00 |
| Apr 3, 2024 | Oppenheimer | Francois Brisebois | Outperform | Upgrade | $10.00 |
| Apr 2, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reinstates | $10.00 |
| Oct 17, 2023 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $8.00 |
| Oct 17, 2023 | Oppenheimer | Justin Kim | Perform | Downgrade | $N/A |
| Aug 9, 2023 | Oppenheimer | Justin Kim | Outperform | Reiterates | $14.00 |
| Jun 30, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $15.00 |
| Jun 22, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 16, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 2, 2023 | Citigroup | Buy | Maintains | $N/A | |
| Jun 1, 2023 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $25.00 |
| May 5, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $15.00 |
Aldeyra Therapeutics Inc. (ALDX) Competitors
The following stocks are similar to Aldeyra based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aldeyra Therapeutics Inc. (ALDX) Financial Data
Aldeyra Therapeutics Inc. has a market capitalization of $255.09M with a P/E ratio of -4.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -64.3%.
Valuation Metrics
Market Cap
$255.09M
Enterprise Value
$188.72M
P/E Ratio
-4.5x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+29.5%
Current Ratio
2.7x
Debt/Equity
31.6x
ROE
-64.3%
ROA
-28.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aldeyra Therapeutics Inc. (ALDX) Business Model
About Aldeyra Therapeutics Inc.
What They Do
Develops treatments for immune-mediated diseases.
Business Model
The company focuses on advancing pharmaceutical innovations to address unmet medical needs in inflammation and metabolic conditions. It generates revenue through the development and commercialization of its therapeutic products, which target conditions like dry eye disease and autoimmune disorders.
Additional Information
Aldeyra Therapeutics is positioned within the biopharmaceutical sector, contributing to scientific research and clinical development aimed at improving patient outcomes. Its ongoing research and trials are crucial for introducing new therapies to the market, addressing chronic conditions with limited treatment options and potentially enhancing healthcare practices.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
8
CEO
Dr. Todd C. Brady M.D., Ph.D.
Country
United States
IPO Year
2014
Website
www.aldeyra.comAldeyra Therapeutics Inc. (ALDX) Latest News & Analysis
Latest News
Quick Summary
Aldeyra's Reproxalap awaits FDA decision by March 16, 2026, after a PDUFA extension. Phase 3 trial met symptom endpoints, but the field trial missed the primary endpoint.
Why It Matters
The FDA decision on Aldeyra's Reproxalap by March 2026 is a key catalyst, but missed primary endpoints in trials introduce significant risk, influencing investor sentiment and stock volatility.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Aldeyra Therapeutics (ALDX) announced an extension of the PDUFA target action date for Reproxalap, a treatment for dry eye disease.
Why It Matters
The PDUFA extension for Reproxalap may impact Aldeyra's stock price and market confidence, affecting future revenue potential and overall investment sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Aldeyra Therapeutics' New Drug Application for reproxalap to treat dry eye disease has had its FDA PDUFA target action date extended to March 16, 2026.
Why It Matters
The FDA's extension of the PDUFA date for Aldeyra's reproxalap may delay potential revenue from the drug, impacting the company's stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Aldeyra Therapeutics (ALDX) is expanding its RASP platform into CNS diseases and provided an update on Reproxalap for dry eye in a recent conference call.
Why It Matters
Aldeyra's expansion into CNS diseases and updates on Reproxalap could signify growth potential and diversification, impacting stock performance and investor interest in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Aldeyra Therapeutics is expanding its RASP platform to address CNS diseases linked to inflammation and updated manufacturing details for reproxalap were shared during a recent webcast.
Why It Matters
Aldeyra's expansion into central nervous system diseases and promising preclinical results could enhance its market potential, driving future revenue growth and impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
2 months ago
Quick Summary
Aldeyra Therapeutics CEO Todd C. Brady will speak at the 2025 Jefferies Global Healthcare Conference in London, focusing on the company's therapies for immune-mediated diseases.
Why It Matters
Aldeyra's CEO participation at a major healthcare conference highlights the company's visibility and potential for investor interest, possibly influencing stock performance and market sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ALDX Stock
What is Aldeyra Therapeutics Inc.'s (ALDX) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Aldeyra Therapeutics Inc. (ALDX) has a median price target of $9.50. The highest price target is $13.00 and the lowest is $7.00.
Is ALDX stock a good investment in 2026?
According to current analyst ratings, ALDX has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALDX stock?
Wall Street analysts predict ALDX stock could reach $9.50 in the next 12 months. This represents a 124.1% increase from the current price of $4.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aldeyra Therapeutics Inc.'s business model?
The company focuses on advancing pharmaceutical innovations to address unmet medical needs in inflammation and metabolic conditions. It generates revenue through the development and commercialization of its therapeutic products, which target conditions like dry eye disease and autoimmune disorders.
What is the highest forecasted price for ALDX Aldeyra Therapeutics Inc.?
The highest price target for ALDX is $13.00 from at , which represents a 206.6% increase from the current price of $4.24.
What is the lowest forecasted price for ALDX Aldeyra Therapeutics Inc.?
The lowest price target for ALDX is $7.00 from at , which represents a 65.1% increase from the current price of $4.24.
What is the overall ALDX consensus from analysts for Aldeyra Therapeutics Inc.?
The overall analyst consensus for ALDX is bullish. Out of 8 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.50.
How accurate are ALDX stock price projections?
Stock price projections, including those for Aldeyra Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 5:36 AM UTC